Limiting radiation therapy to lymph nodes on just one side of the neck in patients suffering from advanced tonsil cancer led to good local regional control.

Of the subset of 46 patients treated unilaterally, 72 percent were men, and the average patient age was 59. Sixty-one percent of patients were current or former smokers. The cancer stage/classification for the study group was: TX = 2 percent (1); T1 = 44 percent (20); T2 = 41 percent (19); and T3 = 13 percent (6). The patients' stages of lymph node involvement were: N0 = 11 percent (5); N1 = 13 percent (6); and N2 = 76 percent (35). The prescribed radiation doses were 60-66 Gy to the postoperative bed and involved neck; and 52-54 Gy to the elective neck in 30-33 fractions using a simultaneous integrated boost technique.
The median follow-up period was 2.8 years (range was .4 to 8.7 years). There were no local or regional recurrences reported, meaning the cancer did not recur in the adjacent nodes or the original location of the cancer in any of the patients. Distant metastasis, meaning the cancer spread from the original tumor site to distant organs or lymph nodes, developed in four (9 percent) of the patients. Two patients developed second primary (new) cancers.
"All treatments for cancer—surgery, radiation therapy, chemotherapy—although effective, can cause temporary and/or permanent toxicity which can affect long-term quality of life," said study author Wade Thorstad, MD, chief of Head and Neck Services and associate professor of Radiation Oncology at Washington University School of Medicine. "Our research indicates that for appropriately selected patients with tonsil cancer, the volume of radiation therapy necessary to control the cancer can be significantly reduced, therefore reducing the side effects and toxicity of radiation, while maintaining a high rate of tumor control."
Source-Eurekalert